Sergio M. H.
- Country
- Spain
- Department
- Endocrinology
Research Overview
- Evaluation of Pharmacogenetic-Guided Therapy Versus Standard Treatment in Patients with Uncontrolled Type 2 Diabetes Using Dapagliflozin, Dulaglutide, and Metformin
- Evaluation of Olpasiran in Reducing First Major Cardiovascular Events in Patients with Elevated Lipoprotein(a) Levels: A Double-Blind, Randomized, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 0 of 311 partner sites.
Specializations
Diabetes Management
This investigator specializes in advancing the treatment of Type 2 Diabetes Mellitus, with particular emphasis on developing personalized therapeutic approaches based on genetic factors.
- Personalized Medicine in Diabetes
- Genetic-Based Treatment Optimization
- Glycemic Control Strategies
The research focus encompasses innovative approaches to diabetes management through pharmacogenetic guidance.
Pharmacogenetics
Specialized in the integration of pharmacogenetic principles into clinical practice, particularly in metabolic disease management.
- Genetic Response Patterns
- Treatment Optimization
- Personalized Drug Selection
The investigator explores the relationship between genetic markers and therapeutic responses in diabetic patients.
Treatment Optimization
Focused on developing optimized treatment protocols for patients with inadequately controlled diabetes.
- Standard Treatment Enhancement
- Treatment Response Assessment
- Clinical Outcomes Improvement
The research involves comparing conventional and genetics-based treatment approaches in diabetes care.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.